

CHAD THERAPEUTICS INC

Form 8-K

February 20, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of Earliest Event Reported): February 15, 2008**  
**CHAD Therapeutics, Inc.**  
(Exact Name of Registrant as Specified in its Charter)  
California  
(State or Other Jurisdiction of Incorporation)

1-12214  
(Commission File Number)

95-3792700  
(I.R.S. Employer Identification No.)

21622 Plummer Street, Chatsworth, California  
(Address of Principal Executive Offices) (Zip Code)  
(818) 882-0883  
(Registrant's Telephone Number, Including Area Code)  
Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

The following information is furnished pursuant to Item 7.01, Regulation FD Disclosure.

On February 19, 2008, CHAD Therapeutics, Inc. (the Company ) issued a press release announcing that it closed the sale of assets related to CHAD s oxygen conserving business to Inovo, Inc., for \$5.25 million in cash, pursuant to an asset purchase agreement dated November 16, 2007. A copy of the Company s press release is incorporated herein by reference and is furnished as Exhibit 99.1 to this report.

**Item 8 .01. Other Events.**

The disclosure set forth in Item 7.01 above is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

The exhibit listed below is being furnished with this Form 8-K.

**Exhibit**

**Number**

**Description**

99.1 Press Release, dated February 19, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHAD Therapeutics, Inc.

Date: February 20, 2008

By: /s/ Tracy A. Kern  
Tracy A. Kern  
Chief Financial Officer